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morbidity andmortality, relapse has not altered signiﬁcantly.
We performed a single institution review of relapse
following allo-HSCT in patients with AL examining salvage
therapy and characteristics of long term survivors.
Methods: All adult patients who proceeded to an allo-HSCT
for AL from 1998-2012 (n¼100) were reviewed. 24 relapsed
following allo-HSCT and a detailed review of salvage treat-
ments and outcomes was made. Probability of overall sur-
vival (POS) and 95% conﬁdence interval (CI) were calculated
by actuarial method.
Results: The 5 year POS of the 100 patients with AL pro-
ceeding to allo-HSCT was 71 % (CI 61-80%). Of 24 relapsing
after allo-HSCT, 17 had initial diagnosis AML, and 7 ALL. The
AML groupmedian agewas 49y (range 22-65), 53%male. Ten
patients received sibling donors, 6 unrelated donors and 1
patient a related haplo-identical donor. Relapses were
mostly systemic (14) and extra medullary (EM) 3 of the 17
cases. Median time to relapse was 13 months (3-57). Salvage
treatments were: second allo-HSCT +/- chemotherapy
(chemo) (n¼5); donor lymphocyte infusion (DLI) +/- chemo
(n¼5); chemo +/- withdrawal of immunosuppression (WI)
(n¼4); or palliative/supportive care (n¼3). Ten patients (57%)
achieved complete response (CR), and CR was maintained by
8 patients (47%), with a median follow up 34 months (range
8-66). All deaths (n¼9) were due to disease. All 3 patients
with EM relapse are in ongoing remission.
In the ALL group (n¼7) median age was 22y (range 19-
52), 57% of male. 3 were sibling donor transplants, 3 unre-
lated and 1 patient received a double cord. Relapse was
systemic in 5 patients, and EM in 2. Median time to relapse
was 13 months (range 3-57). Salvage treatments comprised:
chemo +/- WI (n¼3), second allo-HSCT +/- salvage chemo
(n¼2), DLI +/- salvage chemo (n¼1), with 1 patient receiving
novel monoclonal antibody therapy. Three patients achieved
a CR, however, all died, 2 of disease progression. Two patients
remain alive in PR with ongoing salvage treatment to be
determined.
Conclusions: Despite advances in allo-HSCT, long term sur-
vival outcomes for patients with ALL who relapse after allo-
HSCT remain poor. However, in contrast, for patients with
AML who relapse, durable long-term remissions can be
achieved with salvage therapy (with and without second
allo-HSCT) with almost half of our patients (47%) in ongoing
CR at a median of 34 months (range 8-66). As shown in other
studies EM relapse, may be salvaged with good long term
results.331
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Background: Over the last decade, unrelated donors have
become a vital resource for hematopoietic stem cell trans-
plantation (HSCT) and the number of allogeneic HSCT (allo-
HSCT) has increased signiﬁcantly. While invasive fungal
infections (IFIs) remain major concerns in these patients,
data regarding impact of these infections on mortality,length of hospital stay, and hospital charge are limited in the
United States at a national level. Additionally, with many
updates in transplant practice, risk factors for IFIs in these
patients may have changed.
Methods: To assess risk factors and impact of IFIs on
mortality, length of hospital stay, and hospital charges, a
quantitative and cross-sectional design was used to analyze
secondary data from the 2010 Healthcare Cost and Utiliza-
tion Project - Nationwide Inpatient Sample (HCUP NIS)
database. Chi-square test, Mann-Whitney test, and multiple
logistic regression were used for statistical analyses.
Results: A total of 5,753 weighted hospital records of allo-
HSCT were identiﬁed with a mean age of 44.8  19.1 years.
The IFI rate was 7.8% (451), with aspergillosis (30.6%) and
candidiasis (9.6%) as the two most common IFIs. Compared
to patients without IFIs, patients with IFIs had nearly 5 times
higher mortality (25.1% vs. 5.1%), longer hospital stays, and
higher hospital charges (p < .01). Multiple regression ana-
lyses on risk factors conﬁrmed presence of graft-versus-host
disease as a recognized risk factor for IFIs. However, younger
age, female gender, and related donors were also identiﬁed
as risk factors for IFIs in this analysis. The underlying reasons
for these unexpected ﬁndings will be explored.
Conclusions: An analysis of a large U.S. inpatient database
conﬁrmed that allo-HSCT patients with IFIs have higher
mortality and higher health care costs. The risk factors for
IFIs have been identiﬁed that could enable better manage-
ment and control of these infections.332
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Background: ABO typing is not readily available within
donor databases. ABO incompatibility between donor and
recipient is not considered a hurdle to an allogeneic he-
matopoietic stem cell transplantation (ALLOSCT). Conﬂicting
data still exist as to its inﬂuence on graft-versus-host disease
(GVHD), relapse, and survival.
Method: We retrospectively examined the impact of ABO
compatibility on outcomes of 109 patients who underwent
matched unrelated donor (MUD), matched related (REL) and
cord blood (CBU) ALLOSCT at our institution since 01/01/
2010.
Results: Median age was 58 years (range, 19.9- 83.6); 33
(30%) were female; 64 (59%) patients had a myeloid, 34 (31%)
lymhoid, 8 (7%) plasma cell and 3 (3%) had other disorder; 57
(52%) patients received myeloablative, 25 (23%) non-
myeloablative and 27 (25%) received reduced intensity con-
ditioning. The stem cell sources were represented by 78
(72%) MUDs,15 (14%) RELs and 16 (15%) CBUs. 80 (86%) of the
MUD and REL transplants were 10/10, 11 (13%) were 9/10, 1
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transplants were 6/10 or higher match. 56 (52%) patients
were transplanted in CR1/PR1, 39 (36%) had stable disease or
<PR and 13 (12%) had resistant or refractory disease. The
CMV status was 26 (25%) D-/R-; 40 (39%) D-/R+, 5 (5%) D+/R-
and 32 (31%) D+/R+. 61 (56%) patients received ABO
compatible transplant, 26 (24%) had a minor incompatibility
and 22 (20%) had a major incompatibility.
The major ABO incompatibility group showed a trend
towards inferior survival compared to both ABO compatible
or minor ABO incompatible transplants. When evaluating
conditioning regimens separately similar trend was seen
among MA, NMA and RIC transplants, but did not reach
statistical signiﬁcance.
No difference was seen in the following factors: gender,
age at SCT, CMV status, acute or chronic GVHD.
Conclusion: In our experience, the use of a major ABO
incompatible donor may represent a risk factor for outcome
of ALLOSCT. Analysis of a larger cohort of patients may pro-
vide further understanding of the impact of ABO compati-
bility on ALLOSCT outcome.333
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Mismatched Related Haplo e Identical SCT
UPN 11/2488 13/0765
Age(y)/ sex 29 / M 30 / M
Diagnosis Relapsed AML CML - AP
Disease status Progressive diseases Progressive disease
Donor Sister Brother
Age (y)/sex 33 / F 33 / M
Stem cell CD34+/kg 5.88 x 106 5.6 x 106
MNC/kg 4.33 x 108 5.3 x 108
engraftment D+14 D +17
Mucositis Gr II Gr III/ IV
GVHD - Gr I
Stay length 47 days 38 days
D+28 chimerism 100% 100%
status Alive +395 Died +60 DAHTransplant, Tata Medical Center, Kolkata, India; 2 Clinical
Haematology & Bone Marrow Transplant, TMC, Kolkata, India;
3 Tata medical Center, Kolkata, India; 4 Clinical Haematology,
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Five patients with progressive disease were transplanted
using the John’s Hopkins protocol but with IV busulphan
3.2mg/kg/day x 4 days given along with ﬂudarabine. The
donors were all siblings and the graft was peripheral blood
stem cells harvested after 4 days of G-CSF. Table I gives the
details of these patients.
All patients had progressive disease and the patient with
AML in ﬁrst relapse with 30% blasts at the time of transplant
(UPN 11/2488) is now one year post transplant with 100%
donor chimerism and no graft versus host disease.. The
protocol is well tolerated with rapid engraftment ( day +14-
17), a very low incidence of mucositits and no VOD. One
patient with CML and earlier blast transformation who had
received multiple rounds of chemotherapy and was in
accelerated phase at the time of transplant died of respira-
tory failure with a presumptive diagnosis of Diffuse Alveolar
Haemorrhage which could be related to busulphan. The pa-
tient with progressive NK T cell lymphoma who had failed
CHOP, and SMILE rejected his graft after achieving full donor
chimerism and succumbed to sepsis with multi-organ failure
while pancytopenic.
The addition of myelablationwith IV busulphan to the John’s
Hopkins protocol of PT-Cy is feasible and may reduce the
frequency of relapse.334
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26 / M 35 / M 25 / F
CML - AP NK Cell Lymphoma PCL
Progressive disease Progressive disease Progressive disease
Brother Brother Brother
27 / M 38 / M 32 / M
2.24 x 106 5.7 x 106 8.0 x 106
3.46 x 108 12.4 x 108 6.72 x 108
D +15 - D +14
Gr I Gr IV Gr III
-
27 days 36 days 28 days
93% 99.9% (11/09)
64.3% (17/09)
99.8%
Alive +60 Died Alive
